FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898341451> ?p ?o ?g. }

• W2898341451 endingPage "viii340" @default.
• W2898341451 startingPage "viii340" @default.
• W2898341451 abstract "Background: The PARP inhibitor olaparib (Lynparza®) is approved as maintenance therapy in pts with PSR OC who are in complete or partial response to platinum-based chemotherapy. Currently, pts with SD are observed until disease progression; the efficacy of maintenance olaparib in these pts is unknown. In a Phase II study (NCT01081951), progression-free survival (PFS) was significantly prolonged in pts with PSR OC receiving olaparib plus platinum-based chemotherapy followed by maintenance olaparib vs those receiving platinum-based chemotherapy alone (Oza et al. Lancet Oncol 2015). This post hoc analysis evaluated outcomes in pts with SD on scans at the end of chemotherapy and the efficacy of maintenance olaparib vs observation. Methods: In this open-label, multicentre trial, pts with PSR serous OC, primary peritoneal cancer or fallopian tube cancer were randomized to olaparib capsules 200 mg twice daily (bid) on days 1–10 of each 21-day cycle plus paclitaxel and carboplatin AUC 4 on day 1 (n = 81) followed by maintenance olaparib 400 mg bid (continuously), or paclitaxel and carboplatin AUC 6 on day 1 (n = 81) without maintenance olaparib. The latest scan from randomization up to 2 weeks after the final dose of carboplatin was used to assess the best objective RECIST v1.1 response at the end of chemotherapy (blinded independent central review). Results: At the end of chemotherapy, 24 (29.6%) pts who had also received low-dose olaparib and 21 (25.9%) pts without olaparib had SD as their best response (timing of the scan ranged from 2.10 months before to 0.49 months after the last dose of carboplatin). Median PFS, calculated from the end of chemotherapy, was 8.74 months with maintenance olaparib at standard dose vs 5.40 months without maintenance olaparib (hazard ratio 0.50; 95% CI 0.25, 1.00). Delayed responses following the end of chemotherapy occurred in four pts receiving maintenance olaparib (16.7%; two complete and two partial responses) and three pts without maintenance olaparib (14.3%; all partial responses). The number of lines of prior chemotherapy did not appear predictive of PFS benefit. Conclusions: Maintenance olaparib may prolong PFS in OC pts with SD following platinum-based therapy. Clinical trial identification: NCT01081951. Editorial acknowledgement: Editorial assistance was provided by Gillian Keating, Mudskipper Business Limited, funded by AstraZeneca. Legal entity responsible for the study: AstraZeneca. Funding: AstraZeneca. Disclosure: A.M. Oza: Honoraria: Intas Pharma. D. Cibula: Fees for advisory boards: Roche, AstraZeneca. A. Oaknin: Fees for advisory boards: Roche, AstraZeneca, PharmaMar, Clovis Oncology, Tesaro; Support for travel/accommodation: Roche, AstraZeneca, PharmaMar. C. Poole: Honoraria for advisory boards: Pfizer, AstraZeneca, Genomic Health, Lilly; Honoraria for talks: Pfizer, AstraZeneca, Genomic Health; Consultancy fees: Creavo Medical Technologies. R.H.J. Mathijssen: Research funding: Astellas, Bayer, Boehringer Ingelheim, Cristal Therapeutics, Novartis, Pamgene, Pfizer, Roche, Sanofi; Consultation fees: Novartis, Servier; Travel support: Astellas, Pfizer. G.S. Sonke: Research funding: AstraZeneca, Merck, Novartis, Roche. N. Colombo: Honoraria: Genentech, AstraZeneca, PharmaMar; Fees for consulting/advisory boards: Genentech, PharmaMar, AstraZeneca, Clovis Oncology, Pfizer, MSD, Tesaro; Research funding: AstraZeneca. P. Vuylsteke: Fees for advisory boards: AstraZeneca, Roche, Eli Lilly. H. Hirte: Honoraria for advisory boards: AstraZeneca, Roche. J. Pfisterer, L.C. Hanker: Fees for advisory boards: Roche, AstraZeneca, Tesaro. M. Plante: Support for travel/accommodation: AstraZeneca. A. Fielding, V. Haddad, J. Chmielecki: Employee of AstraZeneca. M. Friedlander: Fees for advisory boards: AstraZeneca, MSD. All other authors have declared no conflicts of interest." @default.
• W2898341451 created "2018-11-02" @default.
• W2898341451 creator A5019934933 @default.
• W2898341451 creator A5021894535 @default.
• W2898341451 creator A5026047065 @default.
• W2898341451 creator A5035286316 @default.
• W2898341451 creator A5037650974 @default.
• W2898341451 creator A5048535376 @default.
• W2898341451 creator A5050804752 @default.
• W2898341451 creator A5063661642 @default.
• W2898341451 creator A5064212341 @default.
• W2898341451 creator A5066888430 @default.
• W2898341451 creator A5067053417 @default.
• W2898341451 creator A5067228089 @default.
• W2898341451 creator A5072712459 @default.
• W2898341451 creator A5073232598 @default.
• W2898341451 creator A5073560048 @default.
• W2898341451 creator A5074174053 @default.
• W2898341451 creator A5087341200 @default.
• W2898341451 date "2018-10-01" @default.
• W2898341451 modified "2023-10-18" @default.
• W2898341451 title "Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy" @default.
• W2898341451 doi "https://doi.org/10.1093/annonc/mdy285.158" @default.
• W2898341451 hasPublicationYear "2018" @default.
• W2898341451 type Work @default.
• W2898341451 sameAs 2898341451 @default.
• W2898341451 citedByCount "2" @default.
• W2898341451 countsByYear W28983414512022 @default.
• W2898341451 countsByYear W28983414512023 @default.
• W2898341451 crossrefType "journal-article" @default.
• W2898341451 hasAuthorship W2898341451A5019934933 @default.
• W2898341451 hasAuthorship W2898341451A5021894535 @default.
• W2898341451 hasAuthorship W2898341451A5026047065 @default.
• W2898341451 hasAuthorship W2898341451A5035286316 @default.
• W2898341451 hasAuthorship W2898341451A5037650974 @default.
• W2898341451 hasAuthorship W2898341451A5048535376 @default.
• W2898341451 hasAuthorship W2898341451A5050804752 @default.
• W2898341451 hasAuthorship W2898341451A5063661642 @default.
• W2898341451 hasAuthorship W2898341451A5064212341 @default.
• W2898341451 hasAuthorship W2898341451A5066888430 @default.
• W2898341451 hasAuthorship W2898341451A5067053417 @default.
• W2898341451 hasAuthorship W2898341451A5067228089 @default.
• W2898341451 hasAuthorship W2898341451A5072712459 @default.
• W2898341451 hasAuthorship W2898341451A5073232598 @default.
• W2898341451 hasAuthorship W2898341451A5073560048 @default.
• W2898341451 hasAuthorship W2898341451A5074174053 @default.
• W2898341451 hasAuthorship W2898341451A5087341200 @default.
• W2898341451 hasBestOaLocation W28983414511 @default.
• W2898341451 hasConcept C104317684 @default.
• W2898341451 hasConcept C121608353 @default.
• W2898341451 hasConcept C126322002 @default.
• W2898341451 hasConcept C126894567 @default.
• W2898341451 hasConcept C141071460 @default.
• W2898341451 hasConcept C143998085 @default.
• W2898341451 hasConcept C182979987 @default.
• W2898341451 hasConcept C185592680 @default.
• W2898341451 hasConcept C2776694085 @default.
• W2898341451 hasConcept C2777292972 @default.
• W2898341451 hasConcept C2778239845 @default.
• W2898341451 hasConcept C2778283404 @default.
• W2898341451 hasConcept C2778822529 @default.
• W2898341451 hasConcept C2779138821 @default.
• W2898341451 hasConcept C2779962180 @default.
• W2898341451 hasConcept C2779984678 @default.
• W2898341451 hasConcept C2780427987 @default.
• W2898341451 hasConcept C2781451048 @default.
• W2898341451 hasConcept C55493867 @default.
• W2898341451 hasConcept C71924100 @default.
• W2898341451 hasConcept C82381507 @default.
• W2898341451 hasConceptScore W2898341451C104317684 @default.
• W2898341451 hasConceptScore W2898341451C121608353 @default.
• W2898341451 hasConceptScore W2898341451C126322002 @default.
• W2898341451 hasConceptScore W2898341451C126894567 @default.
• W2898341451 hasConceptScore W2898341451C141071460 @default.
• W2898341451 hasConceptScore W2898341451C143998085 @default.
• W2898341451 hasConceptScore W2898341451C182979987 @default.
• W2898341451 hasConceptScore W2898341451C185592680 @default.
• W2898341451 hasConceptScore W2898341451C2776694085 @default.
• W2898341451 hasConceptScore W2898341451C2777292972 @default.
• W2898341451 hasConceptScore W2898341451C2778239845 @default.
• W2898341451 hasConceptScore W2898341451C2778283404 @default.
• W2898341451 hasConceptScore W2898341451C2778822529 @default.
• W2898341451 hasConceptScore W2898341451C2779138821 @default.
• W2898341451 hasConceptScore W2898341451C2779962180 @default.
• W2898341451 hasConceptScore W2898341451C2779984678 @default.
• W2898341451 hasConceptScore W2898341451C2780427987 @default.
• W2898341451 hasConceptScore W2898341451C2781451048 @default.
• W2898341451 hasConceptScore W2898341451C55493867 @default.
• W2898341451 hasConceptScore W2898341451C71924100 @default.
• W2898341451 hasConceptScore W2898341451C82381507 @default.
• W2898341451 hasLocation W28983414511 @default.
• W2898341451 hasLocation W28983414512 @default.
• W2898341451 hasOpenAccess W2898341451 @default.
• W2898341451 hasPrimaryLocation W28983414511 @default.
• W2898341451 hasRelatedWork W2053778437 @default.
• W2898341451 hasRelatedWork W2311734504 @default.
• W2898341451 hasRelatedWork W2320097775 @default.
• W2898341451 hasRelatedWork W2415960870 @default.

• next